Exbio — Research products — Antibodies — CD and related antigens — Anti-Hu CD135 APC

Anti-Hu CD135 APC

Regulatory status

RUO

Antigen

CD135

Clone

BV10A4

Format

APC

Reactivity

Human

Application

FC (QC tested)

Excitation laser

red (633 nm)

Variant

100 tests

1A-587-T100

Ask for delivery term HERE

220.00 USD

Variant

0.1 mg

11-261-C100

In stock

220.00 USD

Contact distributor

Product details

Description

Images

References

Isotype

Mouse IgG1

Specificity

The mouse monoclonal antibody BV10A4 (BV10) reacts with an extracellular epitope of CD135 (FLT3, FLK2, STK-1), a 130-160 kDa type I transmembrane receptor tyrosine kinase that is involved in early steps of hematopoiesis.

Application

FC (QC tested)

Application details

Flow cytometry: The reagent is designed for analysis of human blood cells using 10 μl reagent / 100 μl of whole blood or 10⁶ cells in a suspension. The content of a vial (1 ml) is sufficient for 100 tests.

Reactivity

Human

Negative species

Mouse

Immunogen

BV-173 leukemic cell line

Preparation

The purified antibody is conjugated with allophycocyanin (APC) under optimum conditions. The conjugate is purified by size-exclusion chromatography.

Formulation

Stabilizing phosphate buffered saline (PBS) solution containing 15 mM sodium azide

Storage and handling

Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. Do not use after expiration date stamped on vial label.

The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.

Other names

FLT3, FLK2, STK1

Antigen description

CD135 / FLT3, also known as FLK2 or STK-1 is a receptor tyrosine kinase that plays important roles in hematopoiesis. After binding of Flt3 ligand (FL), CD135 homodimerizes and stimulates proliferation, differentiation and protects the cell from apoptosis. The loss of CD90 and gain of CD135 expression marks the loss of self-renewal in hematopoietic stem cell population. Detectable CD135 expression appears first at low levels on the surface of primitive multilineage progenitor cells and disappears during defined stages of B-cell development, but is upregulated and maintained during maturation of monocytes. CD135 is also expressed on thymocytes, dendritic cell progenitors and on mature dendritic cells, as well as on various malignant hematopoietic cells.

Entrez Gene ID 2322

UniProt ID P36888

Flow cytometry surface staining pattern of REH cell suspension stained using anti-human CD135 (BV10A4) APC antibody (10 μl reagent per million cells in 100 μl of cell suspension).

Separation of REH cells stained using anti-human CD135 (BV10A4) APC antibody (10 μl reagent per million cells in 100 μl of cell suspension, red-filled) from REH cells stained using mouse IgG1 isotype control (MOPC-21) APC antibody (concentration in sample 5 μg/ml, same as CD135 APC concentration, black-dashed) in flow cytometry analysis (surface staining).

General references:

Kuchenbauer F, Kern W, Schoch C, Kohlmann A, Hiddemann W, Haferlach T, Schnittger S: Detailed analysis of FLT3 expression levels in acute myeloid leukemia. Haematologica. 2005 Dec;90(12):1617-25.
PubMed

Whartenby KA, Calabresi PA, McCadden E, Nguyen B, Kardian D, Wang T, Mosse C, Pardoll DM, Small D: Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease. Proc Natl Acad Sci U S A. 2005 Nov 15;102(46):16741-6.
PubMed

Christensen JL, Weissman IL: Flk-2 is a marker in hematopoietic stem cell differentiation: a simple method to isolate long-term stem cells. Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14541-6.
PubMed

Rappold I, Ziegler BL, Köhler I, Marchetto S, Rosnet O, Birnbaum D, Simmons PJ, Zannettino AC, Hill B, Neu S, Knapp W, Alitalo R, Alitalo K, Ullrich A, Kanz L, Bühring HJ: Functional and phenotypic characterization of cord blood and bone marrow subsets expressing FLT3 (CD135) receptor tyrosine kinase. Blood. 1997 Jul 1;90(1):111-25.
PubMed

Product specific references:

Leukocyte Typing VI., Kishimoto T. et al. (Eds.), Garland Publishing Inc. (1997).

Haylock DN, Horsfall MJ, Dowse TL, Ramshaw HS, Niutta S, Protopsaltis S, Peng L, Burrell C, Rappold I, Buhring HJ, Simmons PJ: Increased recruitment of hematopoietic progenitor cells underlies the ex vivo expansion potential of FLT3 ligand. Blood. 1997 Sep 15;90(6):2260-72.
PubMed

Masuda H, Anwar SS, Bühring HJ, Rao JR, Gargett CE: A novel marker of human endometrial mesenchymal stem-like cells. Cell Transplant. 2012;21(10):2201-14.
PubMed

Variant

100 tests

1A-587-T100

Ask for delivery term HERE

220.00 USD

Variant

0.1 mg

11-261-C100

In stock

220.00 USD

Contact distributor

Datasheet download